Results 31 to 40 of about 9,765 (234)

The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization

Journal of General Virology, 2011
Hepatitis C virus (HCV) non-structural protein 5A (NS5A) is a multi-functional protein that is expressed in basally phosphorylated (p56) and in hyperphosphorylated (p58) forms. NS5A phosphorylation has been implicated in regulating multiple aspects of HCV replication. We recently reported the identification of a class of compounds that potently inhibit
Dike, Qiu, Julie A, Lemm, Donald R, O'Boyle, Jin-Hua, Sun, Peter T, Nower, Van, Nguyen, Lawrence G, Hamann, Lawrence B, Snyder, Daniel H, Deon, Edward, Ruediger, Nicholas A, Meanwell, Makonen, Belema, Min, Gao, Robert A, Fridell   +13 more
openaire   +2 more sources

NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains.

PLoS Pathogens, 2017
Hepatitis C virus (HCV) RNA is synthesized by the replicase complex (RC), a macromolecular assembly composed of viral non-structural proteins and cellular co-factors.
Tiffany Benzine, Ryan Brandt, William C Lovell, Daisuke Yamane, Petra Neddermann, Raffaele De Francesco, Stanley M Lemon, Alan S Perelson, Ruian Ke, David R McGivern   +9 more
doaj   +1 more source

Complete replication of hepatitis C virus in cell culture. [PDF]

, 2005
Many aspects of the hepatitis C virus (HCV) life cycle have not been reproduced in cell culture, which has slowed research progress on this important human pathogen.
Burton, Dennis R, Evans, Matthew J, Hynes, Richard O, Lindenbach, Brett D, Liu, Christopher C, Maruyama, Toshiaki, McKeating, Jane A, Rice, Charles M, Syder, Andrew J, Tellinghuisen, Timothy L, Wölk, Benno   +10 more
core   +1 more source

Potent Hepatitis C Virus NS5A Inhibitors Containing a Benzidine Core [PDF]

ACS Medicinal Chemistry Letters, 2013
Here we report the discovery of a series of potent hepatitis C virus (HCV) NS5A inhibitors based on the benzidine prolinamide backbone. Taking a simple synthetic route, we developed a novel inhibitor structure, which allows easy modification, and through optimization of the capping group, we identified compound 6 with highly potent anti-HCV activity ...
Bae, IH, Choi, JK, Chough, C, Keum, SJ, Kim, H, Jang, SK, Kim, BM   +6 more
openaire   +3 more sources

Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy [PDF]

, 2014
Hepatitis C virus (HCV) infection represents an important public health problem worldwide. Reduction of HCV morbidity and mortality is a current challenge owned to several viral and host factors.
Carpio Pedroza, Juan Carlos, Cruz Rivera, Mayra, Escobar Gutierrez, Alejandro, Fonseca Coronado, Salvador, Martinez Guarneros, Armando, Preciado, María Victoria, Rahal, Paula, Ruiz Tovar, Karina, Valva, Pamela, Vazquez Chacon, Carlos, Yamasaki, Lilian   +10 more
core   +1 more source

Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection. Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program [PDF]

, 2016
Background and Aims: An HCV cure is now possible in a large proportion of HIV-HCV patient. We present real life results of a compassionate use program promoted by SIMIT (Infectious and Tropical Diseases Italian Society) of Dasabuvir and Ombitasvir ...
Andreoni, M., Angarano, G., Antinori, A., Boffa, N., Bruno, R., Cacopardo, B., Castelli, F., Cattelan, A., Chirianni, A., De Luca, A., Di Biagio, A., Di Perri, G., D’Arminio Monforte, A., Galli, M., Gentilotti, E., Giacometti, A., Gori, A., Lazzarin, A., Maggiolo, F., Mastroianni, C. M., Mussini, C., Parruti, G., Pasquazzi, C., Pennica, A., Puoti, M., Ricciardi, A., Rizzardini, G., Sarmati, L., Sighinolgi, L., Taliani, G., Teti, E., Vullo, V.   +31 more
core   +1 more source

An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains.

PLoS ONE, 2017
The objective was to develop a method of HCV genome sequencing that allowed simultaneous genotyping and NS5A inhibitor resistance profiling. In order to validate the use of a unique RT-PCR for genotypes 1-5, 142 plasma samples from patients infected with
Elisabeth Andre-Garnier, Bernard Besse, Audrey Rodallec, Olivier Ribeyrol, Virginie Ferre, Caroline Luco, Laura Le Guen, Nathalie Bourgeois, Jérôme Gournay, Eric Billaud, François Raffi, Marianne Coste-Burel, Berthe-Marie Imbert-Marcille   +12 more
doaj   +1 more source

Protein Inhibitor of Activated STAT2 Restricts HCV Replication by Modulating Viral Proteins Degradation

Viruses, 2017
Hepatitis C virus (HCV) replication in cells is controlled by many host factors. In this report, we found that protein inhibitor of activated STAT2 (PIAS2), which is a small ubiquitin-like modifier (SUMO) E3 ligase, restricted HCV replication.
Jing Guo, Dan Chen, Xiaoxiao Gao, Xue Hu, Yuan Zhou, Chunchen Wu, Yun Wang, Jizheng Chen, Rongjuan Pei, Xinwen Chen   +9 more
doaj   +1 more source

Management of direct antiviral agent failures [PDF]

Clinical and Molecular Hepatology, 2016
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAAs). Most HCV patients treated with these drugs achieve viral elimination, but 1% to 15% fail to attain this ...
María Buti, Rafael Esteban
doaj   +1 more source

The Role of RASs /RVs in the Current Management of HCV

Viruses, 2021
The approval of combination therapies with direct-acting antiviral (DAA) regimens has led to significant progress in the field of hepatitis C virus (HCV) treatment.
Konstantinos Malandris, Georgios Kalopitas, Eleni Theocharidou, Georgios Germanidis   +3 more
doaj   +1 more source